Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. - Wikidata - awgldk - TriplyDB

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

http://www.wikidata.org/entity/Q36497201

about

Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor Targeted therapies in development for non-small cell lung cancer RAS diseases in children Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers Optimizing biologically targeted clinical trials for neurofibromatosis.PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development.Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Preclinical efficacy of MEK inhibition in Nras-mutant AML.Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.Emerging EPO and EPO receptor regulators and signal transducers.Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.The genomic landscape of juvenile myelomonocytic leukemia.Ginsenoside Rg1 improves bone marrow haematopoietic activity via extramedullary haematopoiesis of the spleen.MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.KRAS insertion mutations are oncogenic and exhibit distinct functional properties.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation.Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma The role of nerve microenvironment for neurofibroma development.Neurofibromin-deficient myeloid cells are critical mediators of aneurysm formation in vivo.Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.Translational hematology.Extramedullary hematopoiesis (EMH) in laboratory animals: offering an insight into stem cell research.Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.Turning the tide in myelodysplastic/myeloproliferative neoplasms.Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.Modeling RASopathies with Genetically Modified Mouse Models.Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

P2860

Q26851000-047EB8DB-47CB-4865-85B4-CBFC17522B37 Q27003534-DB8F68C1-0E67-4780-ABED-2FB3BD3AC22C Q27022852-C90B1C66-CA11-43FD-8ACE-85F65BB1E334 Q28252058-FA2CFCBF-01ED-4C8D-AEFD-B619610AC4A5 Q28829666-7E51A37D-8E76-4771-8AD9-67FE1F2684E4 Q30438898-875519FA-8D91-4EA2-AA7A-7DFEEC131C3B Q33556937-AA4156D8-8572-45A2-BF18-0222E79E1814 Q33685977-6D445A38-26EE-4EE5-8CDF-9703E3C44205 Q33917204-CB656723-FA81-4D9C-B542-682C87BFED35 Q34430736-9DE43078-6900-4C9E-BE73-B7213BEAFF9B Q34625410-6212090F-36CF-4DF1-8D35-ACA1208D192D Q34662946-DDD3FD19-A010-427A-A7C2-F5D76B67CB32 Q34737521-22921189-DCC1-48AC-890C-3580C03DC0E2 Q34797988-51B42FDD-00EF-487E-8E16-DB52ACF3CA20 Q35657827-466BDBE8-DD18-4606-9164-1C782EDD8A5A Q35692391-0673C3AD-B910-4FAE-88F1-E1EE4B678100 Q35788976-C12DAC2C-93DF-4B43-BA97-3C23C842164F Q35987649-0A7634D6-7041-4D37-8CD2-C9FE5C0284D3 Q36225715-5B6B3A2A-B827-482F-8725-87BEFD20A66D Q36232829-84FCCC7E-DBB6-4142-9E65-02E6A66BFB4E Q36497139-E234FAE4-4C8E-4E3D-A4BB-7FF4A3780345 Q36564695-0994B78C-D092-4AC4-BC21-E5B63D6FCFCD Q36708989-003BDDBF-9041-4074-97D6-0582CE87BF03 Q36928346-2478D12C-B5E6-49C2-A594-011365FA8C31 Q36957609-6210DA5E-4ADF-4C25-9A45-7BB06334416D Q37304113-60E2F095-D22F-4345-9F7D-130855E5A97C Q37415475-81964DB8-6CA0-4E12-A642-E9E74E92043F Q37455251-1431752E-BBD1-4908-83F4-30586C2030AD Q37463973-4B833196-F86C-420C-8E93-B2F962900A6E Q37515982-582E8FAE-A25D-4B8A-97A2-C474E8521CA4 Q37641630-EC6FE99A-6F25-4974-9B4B-4F1BFC9BAE74 Q37649834-5B667431-46DC-4634-ACDB-A677142D1B2F Q37679937-AD3DB1B7-6E4E-4ED6-A864-2BEE794DB541 Q38247744-4A5D045B-448D-4605-90FD-AB21072D6E8A Q38342415-AB265B40-5F6C-44AC-9A81-EEBFA579CAA2 Q38636749-9D32342D-EB4D-4086-B91D-5DEA1F18ED8F Q38712988-8B1C6732-D2F7-498C-9534-D39BE5B7A322 Q39030536-A1E78B82-15EC-4A41-B108-BC7220D84E49 Q39031139-C48AF783-7B5A-463E-8271-0E7CD81B75EE Q39144248-3CC582AA-5AA6-40F0-8835-ECDA6B14DFFE

P2860

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

http://www.wikidata.org/entity/Q36497201

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

@ast

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

@en

type

label

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

@ast

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

@en

prefLabel

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

@ast

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

@en

P1433

Q36497201-740411B0-CC7C-47D4-B382-BDE45D07A604

P1476

Q36497201-AC85F8B2-18CD-4600-9DF4-C1F09DD166EF

P2093

Q36497201-1CC4E9DD-6412-4432-AC2B-853950DECEE8

Q36497201-287A863C-F0CE-49DA-A7B9-E03903FE19CF

Q36497201-31C43FC5-FF88-4963-8950-C9056E13399C

Q36497201-440351E2-9E99-4326-AA64-58B409CDB15D

Q36497201-76E832CE-A34F-47D6-AC27-FDA844136E4A

Q36497201-8A331086-6CC3-499E-9800-6632BCDA0F14

Q36497201-8D5C81FE-39D1-41E2-8C81-02BFC6F8254F

Q36497201-AD1C010A-D897-4A76-8DD4-71CC652E2BCE

Q36497201-BBB07553-D625-4A8B-A2AA-4032921E381F

P2860

Q36497201-0229AC37-DA83-4118-B99C-3CA8A64DE324

Q36497201-041D2725-24C7-4F17-9D43-7E65943D35E2

Q36497201-31089D00-3CC3-42E0-A367-0C2CA724B43B

Q36497201-31E58C6A-119D-4BD5-B644-3BD35D95AEB6

Q36497201-3D776F95-DA8C-4A66-BA6D-AFF07CFF700F

Q36497201-4B914378-643B-45E9-BA2A-261754445225

Q36497201-5918D8CE-A399-4740-A19D-52FE09603533

Q36497201-7C731C01-A44E-40E1-8827-ADAA44FC1B6D

Q36497201-89031B37-57A6-4388-B18D-441661F4622E

Q36497201-8EDE3029-8E3A-44A7-884A-6A72AAB4E8BA

P304

Q36497201-4034FDF8-C6AE-4705-BF3E-FEE6DADDFEE0

P31

Q36497201-B0357BEC-BFC9-4E4C-B018-0D4D3D35927F

P356

Q36497201-E5A4A7ED-18C6-4D22-A8D9-5C2F48826862

P407

Q36497201-4038706D-CA36-4604-B302-4D9AEFCEDA3A

P433

Q36497201-ED044EFF-2759-4B51-A718-F08D47A44940

P478

Q36497201-B6FC61F4-C1A1-459B-9F7E-6563C3827315

P577

Q36497201-EC182110-A7FA-4545-9B12-1BA17FBA3F7A

P698

Q36497201-483283F0-AD23-4DB7-8E92-D02542685237

P932

Q36497201-0F995C81-2CF4-4BFA-A752-931D4B6CC34D

P356

P1433

Journal of Clinical Investigation

P1476

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

@en

P2093

Benjamin S Braun

http://www.w3.org/2001/XMLSchema#string

Emily Harding Theobald

http://www.w3.org/2001/XMLSchema#string

Jennifer O Lauchle

http://www.w3.org/2001/XMLSchema#string

Jin Xu

http://www.w3.org/2001/XMLSchema#string

Jon Akutagawa

http://www.w3.org/2001/XMLSchema#string

Kevin Shannon

http://www.w3.org/2001/XMLSchema#string

Kimberly Krisman

http://www.w3.org/2001/XMLSchema#string

Scott Kogan

http://www.w3.org/2001/XMLSchema#string

Tiffany Chang

http://www.w3.org/2001/XMLSchema#string

P2860

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

NF1 tumor suppressor gene function: narrowing the GAP

Germline KRAS mutations cause Noonan syndrome

Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

A clonogenic common myeloid progenitor that gives rise to all myeloid lineages

Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy.

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

P304

335-339

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI63193

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23221337

http://www.w3.org/2001/XMLSchema#string

P932

3533281

http://www.w3.org/2001/XMLSchema#string